Human IL-18(Interleukin 18) ELISA Kit
中文名称:人白介素18(IL-18)酶联免疫吸附测定试剂盒
别称:
IL18、IGIF、IL-1g、IL-1F4、Interferon-gamma-inducing factor
Price:
Size:
96T
48T
96T*5
- 反应性: Human
- 检测范围: 15.63-1000 pg/mL
- 灵敏度: 9.38 pg/mL
产品应用 | ELISA |
检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人IL-18抗体包被于酶标板上,实验时样品(或标准品)中的人IL-18会与包被抗体结合。后依次加入生物素化的抗人IL-18抗体和辣根过氧化物酶标记的亲和素,抗人IL-18抗体与结合在包被抗体上的人IL-18结合,生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450 nm波长处测OD值,IL-18浓度与OD450值之间呈正比,通过绘制标准曲线计算出样品中IL-18的浓度。 |
反应类型 | Sandwich-ELISA |
规格 |
96T
/ 48T
/ 96T*5
|
反应时间 | 3.5h |
反应性 | Human |
检测方法 | Colormetric |
检测范围 | 15.63-1000 pg/mL |
灵敏度 | 9.38 pg/mL |
样本体积 | 100μL |
样本类型 | 血浆,细胞上清,细胞提取液体,组织匀浆等其他生物体液 |
特异性 | 可检测样本中的人IL-18,且与其它类似物无明显交叉反应 |
精密度 | 板内,板间变异系数均<10% |
回收率 | 80%-120% |
储存条件 | 2-8℃/-20℃ |
数据处理 |
-
Klebsiella pneumoniae induces inflammatory bowel disease through caspase-11-mediated IL-18 in the gut epithelial cells
IF: 8.797Journal:Cellular and Molecular Gastroenterology and Hepatology -
Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site
IF: 8.469 -
Hypoxia-Induced HIF-1α Expression Promotes Neurogenic Bladder Fibrosis via EMT and Pyroptosis
IF: 7.666Journal:Cells -
N-3 polyunsaturated fatty acids protect esophageal epithelial cells from acid exposure
IF: 7.425 -
Autophagy promotes GSDME-mediated pyroptosis via intrinsic and extrinsic apoptotic pathways in cobalt chloride-induced hypoxia reoxygenation-acute kidney injury
IF: 7.129 -
Long Noncoding RNA MIAT Regulates Hyperosmotic Stress-Induced Corneal Epithelial Cell Injury via Inhibiting the Caspase-1-Dependent Pyroptosis and Apoptosis in Dry Eye Disease
IF: 6.922 -
CCN1/Integrin α5β1 Instigates Free Fatty Acid-Induced Hepatocyte Lipid Accumulation and Pyroptosis through NLRP3 Inflammasome Activation
IF: 6.706Journal:Nutrients -
Autophagy-Based Unconventional Secretory for AIM2 Inflammasome Drives DNA Damage Resistance During Intervertebral Disc Degeneration
IF: 6.684 -
Acrylamide Induces Neurotoxicity in SH-SY5Y Cells via NLRP3-mediated Pyroptosis
IF: 5.682Journal:MOLECULAR NEUROBIOLOGY -
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia
IF: 5.554Journal:AIDS